OTC Markets OTCQB - Delayed Quote USD

MediPharm Labs Corp. (MEDIF)

0.0520

+0.0020

+(4.00%)

At close: January 10 at 3:58:29 PM EST

MediPharm Labs Enters Landmark Commercial Agreement with Laboratório Teuto in Brazil

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm" or the "Company"), a leader in pharmaceutical-grade cannabis manufacturing, is proud to announce a commercial agreement with Laboratório Teuto ("Teuto"), a leading pharmaceutical manufacturer and marketer in Brazil. This partnership signifies a significant milestone as MediPharm expands its reach into one of the most tightly regulated medical cannabis markets globally.

CNW Group 3 days ago

MEDIF
+4.00%
TSX Penny Stocks With Market Caps Over CA$20M To Consider

The Canadian market has recently experienced a pullback, with the TSX index losing about 6.5% since its peak in December, reflecting uncertainties in political leadership and policy shifts. Despite these challenges, the underlying economic growth and easing inflation present opportunities for investors willing to navigate this volatility. For those interested in smaller or newer companies, penny stocks—though an older term—remain a relevant investment area; when backed by strong financials,...

Simply Wall St. 19 days ago

MEDIF
+4.00%
BCBNF

MGAFF
MediPharm Labs to Sell its Napanee Facility to Kensana Health for $5.5M

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company") and Kensana Health Inc. ("Kensana Health") are pleased to announce that they have entered into a share purchase agreement (the "Purchase Agreement") for the purchase and sale of MediPharm's facility in Napanee, Ontario (the "Napanee Facility") through a disposition of all of the Company's indirect equity interests in its wholly-owned subsidiary ABcann Medicinals Inc. ("ABcann") to Kensana Health for

CNW Group 25 days ago

MEDIF
+4.00%
MediPharm Labs Reports Third Quarter Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three and nine months ended September 30, 2024.

PR Newswire last month

MEDIF
+4.00%
3 TSX Penny Stocks With Market Caps Under CA$30M To Consider

The Canadian market, like its U.S. counterpart, has been experiencing a notable upswing following the recent decisive election outcome in the United States, which has cleared a significant source of uncertainty for investors. Amid this backdrop of shifting political landscapes and economic fundamentals, penny stocks continue to capture interest as potential investment opportunities due to their affordability and growth potential. While the term "penny stocks" may seem outdated, these...

Simply Wall St. last month

MEDIF
+4.00%
WPNDF

BTLLF
MediPharm Labs Sets Date to Report Third Quarter 2024 Financial Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its third quarter financial results for the three and nine months ended September 30, 2024, before markets open on Thursday, November 14, 2024.

CNW Group last month

MEDIF
+4.00%
MediPharm Labs Announces Departure of President and Co-Founder Keith Strachan

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company"), a specialized, research-driven company focused on pharmaceutical-quality cannabis extraction and cannabis based health products, is announcing that President and Co-Founder Keith Strachan will be stepping down from his management position effective December 31, 2024. Keith will continue to provide strategic support and guidance to the Company by joining the Board of Directors effective January 1, 20

CNW Group 2 months ago

MEDIF
+4.00%
MediPharm Labs Announces $2.1M Debt Repayment

MediPharm Labs Corp. ("MediPharm" or the "Company") (TSX: LABS), a specialized, research-driven pharmaceutical company focused on cannabis-based health products, is pleased to announce that it has paid off the entire remaining convertible debt amount of $2.1 million, leaving the Company materially debt-free.

CNW Group 3 months ago

MEDIF
+4.00%
MediPharm Labs Reports Second Quarter Results Closing in on Positive Adjusted EBITDA(1) as Gross Profit Continues to Improve

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three and six months ended June 30, 2024 ("Q2 2024").

PR Newswire 4 months ago

MEDIF
+4.00%
/R E P E A T -- MediPharm Labs Sets Date to Report Second Quarter 2024 Financial Results/

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its second quarter financial results for the period ended June 30, 2024, before markets open on Wednesday, August 14, 2024.

CNW Group 4 months ago

MEDIF
+4.00%
MediPharm Labs Announces Voting Results From the 2024 Annual Meeting of Shareholders

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual meeting of holders of common shares ("Shareholders") held on Wednesday, June 26, 2024 (the "Meeting"). The voting results for each of the matters presented at the Meeting are outlined below.

PR Newswire 6 months ago

MEDIF
+4.00%
MediPharm Labs Acquires Advanced Medical Cannabis Delivery Method Technology from Remidose Aerosols

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has entered into a licencing agreement with Remidose Aerosols Inc. ("Remidose") to acquire the exclusive rights for advanced cannabis products (the "Agreement").

CNW Group 6 months ago

MEDIF
+4.00%
MediPharm Labs Reports First Quarter Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three months ended March 31, 2024.

CNW Group 7 months ago

MEDIF
+4.00%
MediPharm Labs Sets Date to Report First Quarter 2024 Financial Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its first quarter financial results for the period ended March 31, 2024, before markets open on Wednesday, May 15, 2024.

PR Newswire 7 months ago

MEDIF
+4.00%
MediPharm Labs Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

MediPharm Labs ( TSE:LABS ) Full Year 2023 Results Key Financial Results Revenue: CA$33.1m (up 50% from FY 2022). Net...

Simply Wall St. 9 months ago

MEDIF
+4.00%
MediPharm Labs Provides Conference Call Recording Details

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, has released and hosted a conference call regarding its full year and fourth quarter financial results for the period ended December 31, 2023.

CNW Group 9 months ago

MEDIF
+4.00%
MediPharm Labs Reports Fourth Quarter and Full Year Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2023.

CNW Group 9 months ago

MEDIF
+4.00%
MediPharm Labs Provides Update on German Cannabis Legalization

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to provide an update on German cannabis legalization.

CNW Group 9 months ago

MEDIF
+4.00%
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2023 Financial Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its full year and fourth quarter financial results for the period ended December 31, 2023, before markets open on Wednesday, March 27, 2024.

PR Newswire 9 months ago

MEDIF
+4.00%
MediPharm Labs Achieves Pharmaceutical GMP Certification with Brazilian Health Authority

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce receipt of GMP certification for their Barrie, Ontario facility from ANVISA, the governing body of Brazil's pharmaceutical industry. MediPharm Labs now has GMP certification from the United States FDA, European Union, Australia's TGA and holds a drug establishment license from Health Canada.

CNW Group 10 months ago

MEDIF
+4.00%

Performance Overview

Return	MEDIF	S&P/TSX Composite index
YTD	+18.18%	+0.60%
1-Year	0.00%	+18.10%
3-Year	-68.86%	+17.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MediPharm Labs Corp. (MEDIF)

MediPharm Labs Enters Landmark Commercial Agreement with Laboratório Teuto in Brazil

TSX Penny Stocks With Market Caps Over CA$20M To Consider

MediPharm Labs to Sell its Napanee Facility to Kensana Health for $5.5M

MediPharm Labs Reports Third Quarter Results

3 TSX Penny Stocks With Market Caps Under CA$30M To Consider

MediPharm Labs Sets Date to Report Third Quarter 2024 Financial Results

MediPharm Labs Announces Departure of President and Co-Founder Keith Strachan

MediPharm Labs Announces $2.1M Debt Repayment

MediPharm Labs Reports Second Quarter Results Closing in on Positive Adjusted EBITDA(1) as Gross Profit Continues to Improve

/R E P E A T -- MediPharm Labs Sets Date to Report Second Quarter 2024 Financial Results/

MediPharm Labs Announces Voting Results From the 2024 Annual Meeting of Shareholders

MediPharm Labs Acquires Advanced Medical Cannabis Delivery Method Technology from Remidose Aerosols

MediPharm Labs Reports First Quarter Results

MediPharm Labs Sets Date to Report First Quarter 2024 Financial Results

MediPharm Labs Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

MediPharm Labs Provides Conference Call Recording Details

MediPharm Labs Reports Fourth Quarter and Full Year Results

MediPharm Labs Provides Update on German Cannabis Legalization

MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2023 Financial Results

MediPharm Labs Achieves Pharmaceutical GMP Certification with Brazilian Health Authority

Performance Overview